title: Reactogenicity and immunogenicity of a three-component acellular pertussis vaccine administered as the primary series to 2, 4 and 6 month old infants in the United States.
abstract: Five hundred and fifty-seven infants received either an acellular pertussis (DTaP) vaccine containing pertussis toxoid (PT), filamentous hemagglutinin (FHA) and pertactin (PRN) or one of two commercially available whole-cell pertussis (DTP) vaccines at 2, 4 and 6 months. One month after the third immunization, IgG antibody values to pertussis toxoid, filamentous hemagglutinin and PRN were significantly greater following DTaP than either DTP (P < 0.05). When reactions within 48 h after all three doses of vaccine were combined, fever 101 degrees, > or = moderate fussiness, > or = moderate pain, swelling 10 mm, and erythema 10 mm occurred less often after DTaP compared with DTP-Connaught (P < 0.001). The same adverse events were also less after DTaP compared with DTP-Lederle (P < 0.05), except for erythema 10 mm. This three-component DTaP vaccine produced fewer adverse events and greater antibody values to PT, FHA and PRN in comparison with either licensed DTP vaccine when given as the primary series.
authors.affiliation: Temple University School of Medicine, Philadelphia, PA, USA.
authors.forename: H H
authors.initials: HH
authors.lastname: Bernstein
authors.forename: E P
authors.initials: EP
authors.lastname: Rothstein
authors.forename: M E
authors.initials: ME
authors.lastname: Pichichero
authors.forename: J L
authors.initials: JL
authors.lastname: Green
authors.forename: K S
authors.initials: KS
authors.lastname: Reisinger
authors.forename: M M
authors.initials: MM
authors.lastname: Blatter
authors.forename: J
authors.initials: J
authors.lastname: Halpern
authors.forename: A M
authors.initials: AM
authors.lastname: Arbeter
authors.forename: D I
authors.initials: DI
authors.lastname: Bernstein
authors.forename: V
authors.initials: V
authors.lastname: Smith
mesh_terms: D018829:Adhesins, Bacterial / Q000276:immunology; D000907:Antibodies, Bacterial / Q000096:biosynthesis; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology; D001886:Bordetella pertussis / Q000276:immunology*; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000009:adverse effects* / Q000276:immunology*; D004311:Double-Blind Method; D005260:Female; D006388:Hemagglutinins / Q000276:immunology; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D008297:Male; D011446:Prospective Studies; D014121:Toxoids / Q000276:immunology; D010566:Virulence Factors, Bordetella
chemical_list: D018829:Adhesins, Bacterial; D000907:Antibodies, Bacterial; D001425:Bacterial Outer Membrane Proteins; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D006388:Hemagglutinins; D014121:Toxoids; D010566:Virulence Factors, Bordetella; C065273:filamentous hemagglutinin adhesin, Bordetella pertussis; C051093:pertussis toxoid; C068929:pertactin